Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions

Annals of the New York Academy of Sciences

Volumn 1012, Issue , 2004, Pages 326-341

  Richardson, Des R ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

2 pyridylcarboxaldehyde isonicotinoyl hydrazone; Alzheimer's disease; Clioquinol; Friedreich's ataxia; Huntington's disease; Iron; Iron chelators; Iron metabolism; Parkinson's disease; Pyridoxal isonicotinoyl hydrazone

Indexed keywords

2 PYRIDYLCARBOXALDEHYDE ISONICOTINOYLHYDRAZONE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHELATING AGENT; CLIOQUINOL; DEFEROXAMINE; HYDRAZONE DERIVATIVE; IRON; IRON CHELATING AGENT; METAL ION; PYRIDOXAL ISONICOTINOYLHYDRAZONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL MODEL; BLOOD BRAIN BARRIER; BRAIN MITOCHONDRION; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG EFFICACY; FRIEDREICH ATAXIA; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; IRON METABOLISM; IRON TRANSPORT; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; RETICULOCYTE; REVIEW;

ANIMALIA;

EID: 1842608741     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1306.026     Document Type: Review

References (88)

1. HARLEY, A. et al. 1993. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease. Brain Res. 627: 349-353.
2. JELLINGER, K.A. 1999. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14: 115-140.
3. SHOHAM, S. & M.B. YOUDIM. 2000. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell. Mol. Biol. 46: 743-760.
4. OLIVIERI, N.F. & G. BRITTENHAM. 1997. Iron chelating therapy and the treatment of thalassemia. Blood 89: 739-761.
5. WONG, C. & D.R. RICHARDSON. 2003. β-Thalassaemia: emergence of new and improved chelators for treatment. Int. J. Biochem. Cell Biol. 35: 1144-1149.
6. BURDO, J.R. & J.R. CONNOR. 2002. Iron transport in the central nervous system. In Molecular and Cellular Iron Transport, pp. 487-508. Dekker. New York.
7. RICHARDSON, D.R. & P. PONKA. 1997. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta 1331: 1-40.
8. MORGAN, E. 1981. Transferrin biochemistry, physiology, and clinical significance. Mol. Aspects Med. 4: 1-123.
9. GUNSHIN, H. et al. 1997. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388: 482-488.
10. FLEMING, M.D. et al. 1997. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat. Genet. 16: 383-386.
11. JEFFERIES, W.A. et al. 1984. Transferrin receptor on endothelium of brain capillaries. Nature 312: 162-163.
12. FISHMAN, J.B. et al. 1987. Receptor-mediated transcytosis of transferrin across the blood brain barrier. J. Neurosci. Res. 18: 299-304.
13. ROBERTS, R.L. et al. 1993. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J. Cell. Sci. 104: 521-532.
14. TAYLOR, E.M. & E.H. MORGAN. 1990. Developmental changes in transferrin and iron uptake by the brain in the rat. Dev. Brain Res. 55: 35-42.
15. KAWABATA, H. et al. 1999. Molecular cloning of transferrin receptor 2: a new member of the transferrin receptor-like family. J. Biol. Chem. 274: 20826-20832.
16. KAWABATA, H. et al. 2000. Transferrin receptor 2-α supports cell growth both in iron-chelated cultured cells and in vivo. J. Biol. Chem. 275: 16618-16625.
17. RICHARDSON, D.R. & E. BAKER. 1994. Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: the effect of transferrin concentration, chelators, and metabolic probes on transferrin and iron uptake. J. Cell. Physiol. 161: 160-168.
18. TRINDER, D. et al. 1996. Transferrin receptor-independent uptake of diferric transferrin by human hepatoma cells with antisense inhibition of receptor expression. Hepatology 23: 1512-1520.
19. JACOBS, A. 1977. Low molecular weight intracellular iron transport compounds. Blood 50: 433-439.
20. RADISKY, D.C. & J. KAPLAN. 1998, Iron in cytosolic ferritin can be recycled through lysosomal degradation in human fibroblasts. Biochem. J. 336: 201-205.
21. RICHARDSON, D.R. et al. 1996. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism. Blood 87: 3477-3488.
22. HARRISON, P.M. & P. AROSIO. 1996. The ferritins: molecular properties, iron storage function, and cellular regulation. Biochim. Biophys. Acta 1275: 161-203.
23. HENTZE, M.W. & L.C. KÜHN. 1996. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. USA 93: 8175-8182.
24. YOUNG, A.B. 2003. Huntingtin in health and disease. J. Clin. Invest. 111: 299-302.
25. HILDITCH-MAGUIRE, P. et al. 2000. Huntingtin: an iron regulated protein essential for normal nuclear and perinuclear organelles. Hum. Mol. Genet. 9: 2789-2797.
26. JELLINGER, K.A. 2002. Recent developments in the pathology of Parkinson's disease. J. Neural Transm. Suppl. 62: 347-376.
27. TABNER, B.J. et al. 2002. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radical Biol. Med. 32: 1076-1083.
28. WOLOZIN, B. & N. GOLTS. 2002. Iron and Parkinson's disease. Neuroscientist 8: 22-32.
29. EL-AGNAF, O.M. & G.B. IRVINE. 2002. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem. Soc. Trans. 30: 559-565.
30. FAUCHEUX, B.A. et al. 2002. Lack of up-regulatjon of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 83: 320-330.
31. THOMPSON, K. et al. 2003. Mouse brains deficient in H-ferritin have normal iron concentration, but a protein profile of iron deficiency and increased evidence of oxidative stress. J. Neurosci. Res. 71: 46-63.
32. LAVAUTE, T. et al. 2001. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27: 209-214.
33. LEE, P.L. et al. 2002. Polymorphisms in iron-responsive binding protein 2 and lack of association with sporadic Parkinson's disease. Mov. Disord. 17: 1302-1304.
34. BORIE, C. et al. 2002. Association study between iron-related genes polymorphisms and Parkinson's disease. J. Neurol. 249: 801-804.
35. UVERSKY, V.N. et al. 2001. Metal triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein: a possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276: 44284-44296.
36. BECKER, G. & D. BERG. 2001. Neuroimaging in basal ganglia disorders: perspectives for transcranial ultrasound. Mov. Disord. 16: 23-32.
37. ANDERSEN, J.K. 2001. Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease? Novartis Found. Symp. 235: 11-20.
38. BUSH, A.I. & R.E. TANZI. 2002. The galvanization of β-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 99: 7317-7319.
39. GLENNER, G.G. & C.W. WONG. 1984. Alzheimer's disease: initial report of purification and characterization of a novel cerebrovascular protein. Biochem. Biophys. Res. Commun. 120: 885-890.
40. GOLABECK, A. et al. 1995. Amyloid beta-binding protein in vitro and in normal human cerebrospinal fluid. Neurosci. Lett. 191: 79-82.
41. SU, S.W. et al. 2000. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res. 852: 274-278.
42. CHERNY, R.A. et al. 2000. Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J. Struct. Biol. 130: 209-216.
43. CHERNY, R.A. et al. 2002. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30: 665-676.
44. ATWODD, C.S. et al. 1998. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273: 12817-12826.
45. ATWODD, C.S. et al. 2000. Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta 1-42. J. Neurochem. 75: 1219-1233.
46. CURTAIN, C.C. et al. 2001. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276: 20466-20473.
47. OPAZO, C. et al. 2002. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid: Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J. Biol. Chem. 277: 40302-40308.
48. BUSH, A.I. et al. 1994. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265: 1464-1467.
49. LIU, S.T. et al. 1999. Histidine-13 is a critical residue in the zinc-ion induced aggregation of the A beta peptide in Alzheimer's disease. Biochemistry 38: 9373-9378.
50. LEE, J-Y. et al. 2002. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. USA 99: 7705-7710.
51. BUSH, A.I. 2002. Metal completing agents as therapies for Alzheimer's disease. Neurobiol. Aging 23: 1031-1038.
52. ROTTKAMP, C.A. et al. 2001. Redox-active iron mediated beta-amyloid toxicity. Free Radical Biol. Med. 30: 447-450.
53. ROGERS, J.T. et al. 2002. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 277: 45518-45528.
54. DE FELICE, F.G. & ST. FERREIRA. 2002. Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cell. Mol. Neurobiol. 22: 545-563.
55. REGLAND, B. et al. 2001 Treatment of Alzheimer's disease with clioquinol. Dement. Geriatr. Cogn. Disord. 12: 408-414.
56. MASTERS, C. 2002 (April 4). Seventh International Geneva/Springfield Alzheimer's Symposium, Geneva, Switzerland.
57. SHIRAKI, H. 1975. The neuropathology of subacute myelo-optico-neuropathy (SMONS) in the humans: with special reference to the quinoform intoxication. Jpn. J. Med. Sci. Biol. 28: 101-164.
58. ARBISER, J.L. et al. 1998. Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy. Mol. Med. 4: 665-670.
59. PUCCIO, H. & M. KOENIG. 2000. Recent advances in the molecular pathogenesis of Friedreich ataxia. Hum. Mol. Genet. 9: 887-892.
60. BECKER, E. & D.R. RICHARDSON. 2001. Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. Int. J. Biochem. Cell Biol. 33: 1-10.
61. RADISKY, D.C. et al. 1999. The yeast frataxin homologue mediates mitochondrial iron efflux: evidence for a mitochondrial iron cycle. J. Biol. Chem. 274: 4497-4499.
62. BECKER, E. et al. 2002. Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: characterisation of frataxin expression compared to molecules involved in iron metabolism and hemoglobinisation. Blood 99: 3813-3822.
63. MÜIILENHOFF, U. et al. 2002. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum. Mol. Genet. 11: 2025-2036.
64. LESUISSE, E. et al. 2003. Iron use for haem synthesis is under the control of the yeast frataxin homologue (Yfh1). Hum. Mol. Genet. 12: 879-889.
65. EATON, J.W. & M. QIAN. 2002. Molecular basis of cellular iron toxicity. Free Radical Biol. Med. 32: 833-840.
66. BABCOCK, M. et al. 1997. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homologue of frataxin. Science 276: 1709-1712.
67. PUCCIO, H. et al. 2001. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect, and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet. 27: 181-186.
68. ROTIG, A. et al. 1997. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. 17: 215-217.
69. WONG, A. et al. 1999. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. 8: 425-430.
70. RUSTIN, P. et al. 1999. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 354: 477-479.
71. LODI, R. et al. 2001. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann. Neurol. 49: 590-596.
72. HAUSSE, A.O. et al. 2002. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 87: 346-349.
73. RICHARDSON, D.R. et al. 1994. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res. 54: 685-689.
74. PONKA, P. et al. 1979. Mobilization of iron from reticulocytes: identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 97: 317-321.
75. RICHARDSON, D.R. et al. 2001. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim. Biophys. Acta 1536: 133-140.
76. RICHARDSON, D.R. 2003. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy. Exp. Opin. Invest. Drugs 12: 235-245.
77. HOY, T. et al. 1979. Effective iron chelation following oral administration of an isoniazid pyridoxal hydrazone. Br. J. Haematol. 43: 443-449.
78. BRITTENHAM, G.M. 1990. Pyridoxal isonicotinoyl hydrazone: an effective chelator after oral administration. Semin. Hematol. 27: 112-116.
79. RICHARDSON, D.R. et al. 1989. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II), and zinc(II). Biol. Metals 2: 161-167.
80. VITOLO, L.M.W. et al. 1990. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part 2, Formation constants with iron(III) and iron(II). Inorg. Chim. Acta 170: 171-176.
81. RICHARDSON, D.R. et al. 1990. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part 1. Ionisation characteristics of the ligands and their relevance to biological properties. Inorg. Chim. Acta 170: 165-170.
82. RICHARDSON, D.R. & E. BAKER. 1991. The release of iron and transferrin by the human malignant melanoma cell. Biochim. Biophys. Acta 1091: 294-302.
83. RICHARDSON, D.R. & P. PONKA. 1994. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J. Lab. Clin. Med. 124: 660-671.
84. RICHARDSON, D.R. et al. 1995. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferarive agents. Blood 86: 4295-4306.
85. BECKER, E. & D.R. RICHARDSON. 1999. Development of novel aroylhydrazone ligands for iron chelation therapy: the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH) analogues. J. Lab. Clin. Med. 134: 510-521.
86. RICHARDSON, D.R. & P. PONKA. 1998. Pyridoxal isonicotinoyl hydrazone and its analogues: potential orally effective iron-chelating agents for the treatment of iron overload disease. J. Lab. Clin. Med. 131: 306-315.
87. ARMSTRONG, C.M. et al. 2003. Structural variations and formation constants of first-row transition metal complexes of biologically active aroylhydrazones. Eur. J. Inorg. Chem. 2003(6): 1145-1156.
88. BERNHARDT, P.V. et al. 2001. Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy. J. Biol. Inorg. Chem. 6: 801-809.